Synthon begins dosing in Phase I trial of SYD985 to treat metastatic solid tumours

Netherlands-based Synthon Biopharmaceuticals (Synthon) has dosed first patients in a Phase I trial of its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985, to treat metastatic solid tumours.

Source: Drug Development Technology - November 27, 2014 Category: Pharmaceuticals Source Type: news